Compare Merck & Co., Inc. (MRK) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs TotalEnergies SE — how do they compare? Merck & Co., Inc. trades at $129.64 (market cap $321.77B), while TotalEnergies SE trades at $86.88 (market cap $196.06B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and TotalEnergies SE pays the higher dividend (4.82%). Which is the better fit depends on your goals.
| MRK | TTE | |
|---|---|---|
Market Cap | $321.77B | $196.06B |
Sector | Health | Energy |
52-Week High | $131.84 | $93.60 |
52-Week Low | $77.60 | $57.39 |
Enterprise Value | $368.53B | $227.06B |
Dividend Yield | 2.61% | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
TotalEnergies SE (TTE) trades at $87.96, up 2.48% today, with a bullish technical signal and strong analyst support. Recent earnings show mixed quarterly beats, while the company expands in renewables and gas projects. Valuation ratios like P/E of 11.01 and P/S of 0.98 appear attractive relative to sector peers.
The outlook is positive given strategic acquisitions and gas field developments, but risks include revenue declines and legal challenges. With a consensus price target of $94.00 and 57.58% buy ratings, the stock offers upside potential amid energy transition opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
